Infratrac is developing a new near-infrared (NIR) spectroscopy-based technique to identify biomolecules and assess their measure of quality or state of degradation

Infratrac Inc. was awarded a $200,000 cooperative agreement from the Department of Commerce National Institute of Standards and Technology under the Science, Technology, Business and/or Education Outreach federal grant program (CFDA 11.620). The award will support Infratrac's development of a near-infrared spectroscopy-based technique to identify biomolecules and assess their quality or state of degradation for use in quality control during 3D drug printing processes. Specifically, Infratrac will collect near-infrared spectra of known pharmaceutical ingredients, conduct analyses to correlate spectra to known drugs including acetaminophen, create a library of near-infrared spectroscopic standards, test spectral modeling against pharmaceutical quality measures, and define a data framework for in-process near-infrared monitoring of 3D printers. The technology is intended to support personalized medical care through customized drugs. All work will be conducted by Infratrac, as there are no subrecipients listed.

Activities

Infratrac will collect NIR spectra of known ingredient specimens utilized in 3D drug-printing. The company will use advanced computational algorithms to conduct analyses and correlate spectra to known pharmaceuticals. The demonstration tests will be applied to known drugs including acetaminophen.

Expected outcomes

Infratrac will create a library of NIR spectroscopic standards, test NIR modeling against standard pharmaceutical quality measures, and define a data framework for in-process NIR for 3D printers.

Intended beneficiaries

The technology will support patients in receiving personalized medical care with drugs customized to their size, metabolism, allergies, genetics, and taste.

Subrecipient activities

There are no subrecipients in this project.